Emulgel
- 1. FORMULATION AND CHARACTERISATION OF CLARITHROMYCIN EMULGEL FOR TOPICAL DRUG DELIVERY Roll no 103235239751 joshivaibhav88@gmail.com Phn:09988189133 Name of Guide Mr. Gurpreet Singh 1
- 3. Acne vulgaris (acne) is a chronic inflammatory disorder of the sebaceous gland with the formation of comedones, papules, pustules, nodules, and/or cysts as a result of obstruction and inflammation of pilosebaceous units (hair follicles and their accompanying sebaceous gland) It most often affects adolescents when the body starts to produce testosterone, which then stimulates the sebaceous glands to produce excess sebum that is then entrapped in hair follicle. Diagnosis is by examination. Treatment is a variety of topical and systemic agents intended to reduce sebum production, infection, and inflammation and to normalize keratinization. 3
- 4. Mechanism of formation of Acne 4
- 5. 5
- 6. EMULGEL 6
- 7. RATIONALE OF EMULGEL AS TOPICAL DRUG DELIVERY 7
- 8. Advantages of using emulgel as topical drug delivery system 8
- 9. METHOD OF FORMULATION OF EMULGEL OIL PHASE WATER PHASE EMULSION EITHER O/W or W/O EMULSION INCORPORATED IN GEL FLOW CHART OF EMULGEL FORMATION 9
- 12. MECHANISM OF ACTION OF CLARITHROMYCIN Clarithromycin Binds to the 50s and 30s ribosomes It cause the inhibition of RNA dependent protein synthesis It cause protein synthesis inhibition of micro-organism hence cause death of microbes 12
- 13. PREFORMULATION STUDIES Spectrum in methanol 13
- 14. S.NO SOLVENT SOLUBILITY 1. ACETONE 2.13 mg/ml 2. METHANOL 0.67 mg/ml 3. 5.5 PHOSPHATE BUFFER 1.4 mg/ml 4. 6.8 PHOSPHATE BUFFER 0.095mg/ml Partition coefficient The partition coefficient of Clarithromycin in n-octanol: PB (pH -5.5) was found to be 1.98. This indicates that the drug is lipophilic in nature. S.NO SOLVENT 1. N-octanol : 5.5 pH phosphate buffer LITERATURE log P value 1.7 THEORETICAL log P value 1.68 ± 0.05 14
- 15. CALIBARATION CURVE IN DIFFERENT SOLVENT 15
- 16. 16
- 17. 17
- 18. 18
- 19. Drug : Excipient Interaction Study – Drug excipients interactions are studied by Fourier Transform Infra red 19
- 20. Reference FTIR of Clarithromycin Test FTIR of Clarithromycin 20
- 21. FTIR of Carbopol- 940 and Clarithromycin FTIR OF HPMCK4M AND CLARITHROMYCIN 21
- 22. FTIR OF CARBOPOL-934 AND CLARITHROMYCIN MELTING POINT DETERMINATION S.NO LITERATURE VALUE THEORETICAL VALUE 1 222-225 221̊ C ± 1 22
- 24. Formula For Emulgel INGREDIENTS F1 F2 F3 F4 F5 F6 F7 F8 F9 Clarithromycin 1gm 1gm 1gm 1gm 1gm 1gm 1gm 1gm 1gm Oleic acid 2ml 2ml 2ml 2ml 2ml 2ml 2ml 2ml 2ml Light liquid .P 4ml 4ml 4ml 4ml 4ml 4ml 4ml 4ml 4ml Acetone 2ml 2ml 2ml 2ml 2ml 2ml 2ml 2ml 2ml Spans 80 0.5ml 0.5ml 0.5ml 0.5ml 0.5ml 0.5ml 0.5ml 0.5ml 0.5ml Propylene Glycol 5ml 5ml 5ml 5ml 5ml 5ml 5ml 5ml 5ml Tweens 80 1ml 1ml 1ml 1ml 1ml 1ml 1ml 1ml 1ml Methyl paraben 30mg 30mg 30mg 30mg 30mg 30mg 30mg 30mg 30mg Propyl paraben 30mg 30mg 30mg 30mg 30mg 30mg 30mg 30mg 30mg Carbopol 934 1gm 1.2gm 1.3gm - - - - - - Carbopol 940 - - - 1gm 1.2gm 1.3gm - - HPMCK4M - - - - - - 1gm Water q.s q.s q.s q.s q.s q.s q.s 1.2gm 1.3gm q.s q.s 24
- 25. Physical Examination The prepared emulgel formulations were inspected visually for their colour, homogeneity, consistency, grittiness and phase separation. The data is shown in table below. S.no Formulation code Colour Phase Grittiness Homogeneity separation Consistency 1 F1 White None - Excellent +++ 2 F2 White None - Excellent +++ 3 F3 White None - Excellent +++ 4 F4 White None - Excellent +++ 5 F5 White None - Excellent +++ 6 F6 White None - Excellent +++ 7 F7 Transparent None - Fair + 8 F8 Transparent None - Good ++ 9 F9 Transparent None - Good ++ Excellent +++, Good ++, Satisfactory + 25
- 26. Measurement of pH The pH of emulgel formulations was determined by using digital pH meter. One gram of gel was dissolved in 100 ml of distilled water and stored for 2 hours. The measurement of pH of each formulation was done in triplicate and average values were calculated. The data is reported in Graph 26
- 27. Rheological Study The viscosity determined using a Brookfield Viscometer with spindle number 7. The formulations whose viscosity were to be determined was added to a beaker and settle over 30 minutes. at the assay temperature (25±1 ºC) before the measurement were taken. Spindle was lowered perpendicular in to the centre of emulgel taking care that spindle does not touch bottom of the jar and rotated at a speed of 50 rpm for 10 minutes. The spindle was moved up and down giving viscosities at number of points along the path. The average of three readings were taken in 10 minute was noted as the viscosity of gels. The data is reported in graph. 27
- 28. Extrudability Test (Tube Test) Extrudability test is based upon the determination of weight required to extrude 0.5 cm ribbon of Emulgel in 10 sec from lacquered collapsible aluminum tube. The test was performed in triplicate and the average values were calculated. The extrudability was then calculated by using the following formula. Extrudability = Weight applied to extrude emulgel from tube (in gm) / Area (in cm2). The data is shown in Graph 28
- 29. Spreading Coefficient Spreading coefficient was measured on the basis of ‘Slip’ and ‘Drag’ characteristics of Emulgel. The Spreadability is calculated by the following formula and results have been reported in Graph. S = M. L / T 29
- 30. Drug Content Determination Weigh accurately 1 gm of Emulgel and it was dissolved in 100 ml of Methanol. The volumetric flask was kept for 2 hours and shaken well in a shaker to mix it properly. The solution was passed through the filter paper and filtered. The absorbance was measured spectrophotometrically at 288nm after appropriate dilution against corresponding gel concentration as blanks. The drug content determined using standard plot. following formula. Data shown in Table and Graph. Drug content= (concentration X Dilution factor X Volume taken) X Conversion factor FORMULATION DRUG CONTENT F1 F2 F3 F4 F5 F6 F7 F8 F9 91.60 ± 0.37 88.38 ± 0.92 88.26 ± 0.87 89.48 ± 0.61 87.83 ± 0.56 85.63 ± 0.38 86.47 ± 0.85 83.91 ± 0.55 82.24 ± 0.88 30
- 31. 31
- 32. Time (hours) 0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0 9.5 10.0 10.5 11.0 11.5 12.0 F1 0.00±0.00 14.68±0.015 19.19±0.005 22.53±0.02 27.39±0.003 30.11±0.36 36.04±0.23 38.93±0.47 42.27±0.15 46.45±0.89 51.19±0.20 55.21±0.115 56.64±0.65 57.74±0.11 59.09±1.18 60.32±0.32 62.02±1.04 63.32±2.09 64.56±0.42 66.48±0.01 68.18±2.46 70.54±2.06 72.7±0.69 74.14±2.13 74.47±1.27 F2 0.00±0.00 15.44±1.25 20.85±0.31 24.83±0.05 27.81±1.46 31.25±2.24 35.23±0.57 37.66±1.98 40.08±1.11 42.17±2.87 43.39±0.91 46.19±1.32 47.56±0.65 50.85±1.81 53.65±1.90 56.39±2.49 58.43±1.09 60.41±0.26 61.9±2.65 63.06±0.32 64.48±0.51 66.55±2.54 68.33±1.86 69.04±0.74 69.65±0.65 F3 0.00±0.00 11.98±1.77 16.36±1.51 20.61±1.96 23.22±0.55 26.68±0.56 28.46±2.43 30.88±2.02 34.77±2.67 37.42±1.90 40.27±0.32 43.76±1.86 45.48±1.61 47.14±0.34 50.12±0.56 52.20±1.43 54.21±0.33 54.92±0.79 58.56±0.53 59.88±0.7 61.84±0.83 63.2±2.22 65.6±1.48 67.0±1.27 68.43±1.16 F4 0.00±0.00 4.53±0.35 7.883±0.56 12.38±1.13 14.67±2.72 18.17±0.11 19.81±0.96 22.08±2.64 29.69±1.49 34.71±0.13 35.55±2.50 38.49±1.56 41.06±1.84 43.5±2.47 46.69±1.73 47.95±0.15 50.68±2.69 52.39±2.31 55.29±0.69 58.61±0.57 63.06±1.39 65.27±0.21 67.11±1.47 69.69±0.41 71.52±1.54 Cumulative drug release of all formulation from F1 – F5 F5 0.00±0.00 4.66±1.19 18.11±2.42 21.35±1.07 22.99±2.41 23.41±1.93 24.47±0.81 25.34±0.76 26.59±0.93 28.02±1.03 29.66±1.47 31.2±0.57 32.79±1.98 35.24±0.41 38.02±1.61 42.95±0.69 45.42±0.57 49.56±1.77 53.26±0.71 56.08±0.63 61.58±2.85 64.45±0.53 66.21±2.78 68.57±0.58 70.5±2.63 32
- 34. In-vitro Cumulative % Drug Release profile of all formulations 34
- 35. Ex vivo Drug Release Study The ex vivo drug release study of selected formulations (F1 and F4) was carried out in a modified Diffusion cell, using wistar male rat skin using dialysis cell (2.3 cm diameter; 4-16 cm2 area) . Then Emulgel was spread uniformly on the membrane. Phosphate buffer pH 5.5 was used as dissolution media. The donor compartment was kept in contact with receptor compartment. This whole assembly was kept on a magnetic stirrer and the solution on the receptor side was stirred continuously using a magnetic bead and temperature of the cell was maintained at 37°C. Sample (5 ml) was withdrawn at suitable time intervals and replaced with equal amounts of fresh dissolution media. The Samples were analyzed spectrophotometrically at 288 nm . Ex Vivo Cumulative % Drug permeate Profile of Formulation 35
- 36. Analysis of variance on Drug release From the ANOVA table it can be concluded that the drug release is significant because the p value of formulation should be less than 0.05 and the p value for F1 is 9.33 x 10-14 and F4 value is 1.58 x 10-9. 36
- 37. Microbiological assay: Clarithromycin stable topical prepration is used for topical prepration in acne. The most of the microbes cause acne is found to be staphylococcus aureus. The microbiological assay is done to determine the activity of prepared formulation with the strain staphylococcus aureus and the Sabouraud agar Medium Ditch plate technique was used, these technique used for evaluation of bacteriostatic or fungistatic activity of a compound. It is mainly applied for semisolid formulations. Previously prepared Sabouraud’s agar dried plates were used one gram of emulgel are placed in a ditch cut in the plate. After incubation for 18 to 24 hours at 37 ⁰C and then the percent inhibition was measured as follows: % Inhibiton= L2/L1*100 where L1- Total length of the streaked culture. L2- Length of inhibiton. 37
- 38. Formulation MIC(%) ± S.D F1 F2 F3 F4 F5 F6 F7 F8 F9 64.3 ± 1.52 54 ± 2.08 51.6 ± 1.08 54.6 ± 1.5 53.8 ± 1.5 48 ± 1 45 ± 1 44 ± 1 41.6 ± 0.57 Percentage inhibition 38
- 39. COMPARISION WITH MARKETED FORMULATION The microbiological activity of marketed formulation of azythromycin gel is compared with the best formulation (i.e. F1) comparing the percent inhibition the following result was obtained. Comparison between marketed formulation and test formulation 39
- 40. Release kinetics profile of Emulgel F1 and F4 according to Zero order 40
- 41. Release kinetics profile of Emulgel F1 and F4 according to First order 41
- 42. Release kinetics profile of Emulgel F1 and F4 according to Higuchi model 42
- 43. Release kinetics profile of Emulgel F1 and F4 according to Peppas model 43
- 44. Regression analysis (r2) of release data based on best curve-fitting method for different formulations of emulgel of clarithromycin (n=3) Result of kinetics: From the table it can be concluded that the best formulation i.e. F1 follows Higuchi kinetics and F4 follows zero order. And the diffusion mechanism of drug from the both formulation (i.e. F1 and F4) would be Non – Fickian diffusion. 44
- 45. Result and discussion • The solubility of clarithromycin was determined in various solvents. The order of solubility was found out to be Acetone > Methanol > 5.5 phosphate buffer > 6.8 phosphate buffer. • A suitable method for analysis of drug is by UV spectrophotometry. Clarithromycin showed maximum absorption at a wavelength of 288 nm in methanol. The value of correlation coefficient was found to be r2 = 0.9929, which showed linear relationship between concentration and absorbance. Thus, it can be concluded that, beer’s law was obeyed. • Preformulation study for drug-excipients compatibility by FT-IR showed no interaction between drug and selected excipients. • Viscosity studies of various formulations revealed that formulation F1 was better compare to others. 45
- 46. • Various formulation (F1, F2, F3, F4, F5, F6, F7, F8 and F9) were developed by using suitable polymer (Carbopol 934, Carbopol 940 and HPMCK4M) by changing the concentration of polymer (i.e. 1%w/w, 1.2%w/w and 1.3%w.w). • Developed formulations of Clarithromycin were evaluated for the physiochemical parameters such as drug content, viscosity, spreadability, extrudability, pH determination and in vitro diffusion. Anti microbial assay studies also showed the good results of formulation F1 . • On comparison of our formulated Clarithromycin Emulgel (i.e.F1) with Marketed formulation of Azithromycin gel, our formulation showed better MIC(minimum inhibitory concentration). • From all the developed formulation, F1 shows better drug diffusion for a period of 12 hrs, did not produced skin irritation, good Rheological properties, good spreadability, good extrudability and good results of antimicrobial studies. Therefore, it was selected as the best formulation. 46
- 47. •The release rate of drug from F1 formulation is best fitted to Higuchi matrix model given in Table 24. •The most satisfactory formulation-F1 did not show any significant change in drug content, In vitro drug diffusion studies pattern after stability studies at 25°C and at 60%RH and 30 oC and at 65%RH for 3 months . Thus, the objective of the present work of formulation and evaluation of Clarithromycin topical Emulgel has been achieved with success. 47
- 48. PUBLICATIONS 1.Joshi B, Singh G, Rana AC, Saini S, Singla V. Emulgel : A comprehensive review on the recent advances in topical drug delivery. Int Res J Pharm2011;2(11):66-70.(Published) 2. Joshi B, Singh G, Rana AC, Saini S. Development and characterization of Clarithromycin Emulgel for topical delivery. Int J Drug Dev Res2012. (Published) 48
Editor's Notes
- #2: {}